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Purpose of the study
In the era of highly active antiretroviral therapy (HAART),
the incidence of opportunistic infections has decreased
and their natural history has changed. This prospective
study intended to evaluate the effect of HAART on
cytomegalovirus (CMV) viraemia in co-infected patients,
in the absence of specific anti-CMV therapy. We present
the preliminary data of an ongoing Romanian research
grant (CNCSIS 848/2006) on newly diagnosed HIV sero-
positives, in a tertiary care hospital – Prof. Dr. Matei Bals
National Institute of Infectious Diseases, from Bucharest,
Romania – between June 2006 to June 2008.
Methods
Virological (HIV and CMV viraemia) and immunological
(CD4) screening was performed every 3 months. The HIV
viral load was performed by the commercial kit Cobas
TaqMan HIV-1 test (Roche Diagnostics), and the CMV
viremia by RoboGene Human Cytomegalovirus Quantifi-
cation kit (aj Roboscreen). We retested all undetectable
CMV viraemia samples found in patients with CD4 <50/
mmc, by CMV PCR kit (Qiagen Diagnostics). Both PCR
reactions were performed on ABI Prism 7000 (Applied
Biosystems). All the patients having detectable CMV virae-
mia received HAART, including a protease inhibitor.
Summary of results
Up to date, our study has included 102 HIV-infected sub-
jects, who were seropositive for anti-CMV IgG antibodies.
Median follow-up was 17.7 months. The study popula-
tion had the M:F ratio 1:1, the median age of 29 years, and
the median CD4 cell count of 175/mmc. None of the
patients developed signs of CMV infection. At baseline,
CMV viraemia was found detectable in 20 patients (range
59–475.818 copies/ml), of whom seven had CD4<50/
mmc. At the second visit, five new cases of detectable CMV
viremia were found (range 59–21.112 copies/ml), of
which all had >50/mmc. Both molecular biology tech-
niques used for CMV-DNA detection indicated similar
results. Under HAART, all of the detectable CMV loads
which were retested in time (19 out of the 25 samples)
became undetectable at next visits, after a median of 14.5
weeks from the introduction of therapy.
Conclusion
In conclusion, HAART effected the reduction of CMV viral
load, without any specific anti-CMV therapy. As in the
case of other opportunistic infections, history of CMV
infection seemed to have been improved by controlling
HIV infection. CMV viremia detection was useful in early
diagnosis of asymptomatic CMV infection.
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